- Home
- CHRS vs XBIT Comparison
CHRS vs XBIT Comparison
Compare CHRS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- XBIT
- Stock Information
- Founded
- CHRS 2010
- XBIT 2005
- Country
- CHRS United States
- XBIT United States
- Employees
- CHRS N/A
- XBIT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- XBIT Pharmaceuticals and Biotechnology
- Sector
- CHRS Health Care
- XBIT Health Care
- Exchange
- CHRS Nasdaq
- XBIT Nasdaq
- Market Cap
- CHRS 84.2M
- XBIT 93.0M
- IPO Year
- CHRS 2014
- XBIT 2015
- Fundamental
- Price
- CHRS $0.95
- XBIT $2.89
- Analyst Decision
- CHRS Buy
- XBIT
- Analyst Count
- CHRS 3
- XBIT 0
- Target Price
- CHRS $4.68
- XBIT N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- XBIT 185.9K
- Earning Date
- CHRS 08-07-2025
- XBIT 08-11-2025
- Dividend Yield
- CHRS N/A
- XBIT N/A
- EPS Growth
- CHRS N/A
- XBIT N/A
- EPS
- CHRS N/A
- XBIT N/A
- Revenue
- CHRS $272,251,000.00
- XBIT N/A
- Revenue This Year
- CHRS N/A
- XBIT N/A
- Revenue Next Year
- CHRS $99.43
- XBIT N/A
- P/E Ratio
- CHRS N/A
- XBIT N/A
- Revenue Growth
- CHRS 19.87
- XBIT N/A
- 52 Week Low
- CHRS $0.66
- XBIT $2.50
- 52 Week High
- CHRS $2.43
- XBIT $8.32
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- XBIT 49.19
- Support Level
- CHRS $0.73
- XBIT $2.95
- Resistance Level
- CHRS $0.82
- XBIT $3.32
- Average True Range (ATR)
- CHRS 0.04
- XBIT 0.17
- MACD
- CHRS 0.02
- XBIT 0.00
- Stochastic Oscillator
- CHRS 88.02
- XBIT 41.89
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.